Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades'
On CNBC’s “Halftime Report Final Trades,” Stephen Weiss of Short Hills Capital Partners said he still finds Taiwan Semiconductor Manufacturing Company Limited TSM cheap.
On Monday, Taiwan Semiconductor Manufacturing bagged the government’s approval for an additional $7.5 billion infusion into Taiwan Semiconductor Arizona unit, the Taipei Times cited the Department of Investment Review statement.
Amy Raskin of Chevy Chase Trust named Regeneron Pharmaceuticals, Inc. REGN.
Chief District Judge Thomas Kleeh denied Regeneron Pharmaceuticals’ effort to prevent the sale of Amgen Inc’s AMGN Eylea biosimilar. Regeneron filed a notice of its appeal to the U.S. Court of Appeals for the Federal Circuit.
Don’t forget to check out our premarket coverage here
Kari Firestone of Aureus Asset Management picked American Tower Corporation AMT as her final trade.
On Sept. 23, JP Morgan analyst Philip Cusick maintained American Tower with an Overweight rating and raised the price target from $240 to $250.
Joseph M. Terranova of Virtus Investment Partners named Trane Technologies plc TT.
On July 31, Trane Technologies reported better-than-expected second-quarter financial results and raised its FY24 guidance. Revenues grew 13% Y/Y to $5.31 billion, surpassing the consensus of $5.13 billion. Bookings increased 19% Y/Y to$5.34 billion in the quarter. Adjusted EPS of $3.30 surpassed the street view of $3.08.
Price Action:
- Taiwan Semiconductor gained 0.2% to close at $182.35 during Wednesday’s session.
- Regeneron Pharmaceuticals shares fell 1.4% to settle at $1,031.15 on Wednesday.
- American Tower fell 0.4% to close at $235.63 during Wednesday’s session.
- Trane Technologies shares gained 1% to close at $387.70 on Wednesday.
Check This Out:
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Leave a Reply